Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y: Platinum agent-induced hypersensitivity reactions: Data mining of the public

version of the FDA adverse event reporting system, AERS. Int J Med Sci {Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|buy Anti-cancer Compound Library|Anti-cancer Compound Library ic50|Anti-cancer Compound Library price|Anti-cancer Compound Library cost|Anti-cancer Compound Library solubility dmso|Anti-cancer Compound Library purchase|Anti-cancer Compound Library manufacturer|Anti-cancer Compound Library research buy|Anti-cancer Compound Library order|Anti-cancer Compound Library mouse|Anti-cancer Compound Library chemical structure|Anti-cancer Compound Library mw|Anti-cancer Compound Library molecular weight|Anti-cancer Compound Library datasheet|Anti-cancer Compound Library supplier|Anti-cancer Compound Library in vitro|Anti-cancer Compound Library cell line|Anti-cancer Compound Library concentration|Anti-cancer Compound Library nmr|Anti-cancer Compound Library in vivo|Anti-cancer Compound Library clinical trial|Anti-cancer Compound Library cell assay|Anti-cancer Compound Library screening|Anti-cancer Compound Library high throughput|buy Anticancer Compound Library|Anticancer Compound Library ic50|Anticancer Compound Library price|Anticancer Compound Library cost|Anticancer Compound Library solubility dmso|Anticancer Compound Library purchase|Anticancer Compound Library manufacturer|Anticancer Compound Library research buy|Anticancer Compound Library order|Anticancer Compound Library chemical structure|Anticancer Compound Library datasheet|Anticancer Compound Library supplier|Anticancer Compound Library in vitro|Anticancer Compound Library cell line|Anticancer Compound Library concentration|Anticancer Compound Library clinical trial|Anticancer Compound Library cell assay|Anticancer Compound Library screening|Anticancer Compound Library high throughput|Anti-cancer Compound high throughput screening| 2011, 8:332–338.PubMed 8. Evans SJ, Waller PC, Davis S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. https://www.selleckchem.com/products/torin-2.html Pharmacoepidemiol Drug Saf 2001, 10:483–486.PubMedCrossRef 9. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC: A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002, 11:3–10.PubMedCrossRef 10. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM: A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998, 54:315–321.PubMedCrossRef 11. Szarfman A, Machado SG, O’Neill RT: Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 2002, 25:381–392.PubMedCrossRef 12. Bate A, Evans SJ: Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009, 18:427–436.PubMedCrossRef 13. Gould AL: Practical pharmacovigilance analysis strategies. Pharmacoepidemiol

Drug Saf 2003, 12:559–574.PubMedCrossRef 14. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N: Novel statistical tools for monitoring the safety Etomoxir manufacturer Amylase of marketed drugs. Clin Pharmacol Ther 2007, 82:157–166.PubMedCrossRef 15. Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, Gkiozos I, Saif MW, Syrigos KN: Hypersensitivity reactions to docetaxel: Retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011, 156:320–324.PubMedCrossRef 16. Szebeni J, Muggia FM, Alving CR: Complement activation

by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998, 90:300–306.PubMedCrossRef 17. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, Talmon Y: Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001, 1:721–735.PubMedCrossRef 18. Biswal BM: Anaphylaxis following continuous 5-fluorouracil infusion chemotherapy. Aust N Z J Med 1999, 29:743–744.PubMedCrossRef 19. Sridhar KS: Allergic reaction to 5-fluorouracil infusion. Cancer 1986, 58:862–864.PubMedCrossRef 20. Eppinger T, Sperber K: Desensitization to 5-fluorouracil. Allergy Asthma Proc 1999, 20:189–191.PubMedCrossRef 21. Millá Santos A, Sanchiz Medina F: Anaphylactic reaction following i.v. administration of 5-fluorouracil. Cancer Treat Rep 1986, 70:1346.PubMed 22. Meijer BU, de Waard-van der Spek FB: Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix cream).